Mouse models of breast cancer metastasis

Breast Cancer Research

Volumn 8, Issue 4, 2006, Pages

  Fantozzi, Anna ^a   Christofori, Gerhard ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

ANIMAL MODEL; BREAST CANCER; BREAST DEVELOPMENT; CANCER CELL; CANCER RESEARCH; CANCER TRANSPLANTATION; CAUSE OF DEATH; CHEMICAL CARCINOGENESIS; GENE AMPLIFICATION; HUMAN; IN VIVO STUDY; MALIGNANT TRANSFORMATION; METASTASIS; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PROMOTER REGION; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; UPREGULATION; ANIMAL; BREAST TUMOR; DISEASE MODEL; FEMALE; GENE EXPRESSION; GENETICS; PATHOPHYSIOLOGY; PHYSIOLOGY; SECONDARY; UDDER;

ANIMALS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; MAMMARY GLANDS, ANIMAL; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION;

EID: 33846938312     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1530     Document Type: Review

References (113)

1. Weigelt B, Paterse JM, van 't Veer LJ: Breast cancer metastasis: markers and models. Nat Rev Cancer 2005 5:591-602.
2. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, Foster R, Gardner B, Lerner H, Margolese R, et al. Relation of number of positive axiliary nodes to the prognosis of patients with primary broad cancer. An NSABP update. Cancer 1983, 52:1551-1557.
3. Chambers AF, Groom AC, MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2:563-572.
4. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70.
5. Hennighausen L, RobinsoT GW: Think globally, act locally: the making of a mouse mammary gland. Genes Dev 1998, 12: 449-455.
6. Wiseman BS, Werb Z: Stromal effects on mammary gland development and breast cancer. Science 2002, 296:1046-1049.
7. Li Y, Hively WP, Varmus HE: Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene 2000, 19:1002-1009.
8. Siegel PM, Messague J: Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 2003, 3: 807-821.
9. Pollak MN, Schemhammer ES, Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004,4:505-518.
10. Hynes NE, Lane HA: ERTB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341-354.
11. Cavallaro U, Christofori G: Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 2004,4:118-132.
12. Lopez JI, Camenisch TD, Stevens MV, Sands BJ, McDonald J, Schroeder JA: CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res 2005, 65:6755-6763,
13. Ferrara N, Kerbal RS: Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
14. Weidner N: Tumoural vascularity as a prognostic factor in cancer patients: The evidence continues to grow. J Pathol 1998, 184:119-122.
15. Alitalo K, Tammela T, Petrova TV: Lymphangiogenesis in development and human disease. Nature 2005, 438:946-953.
16. Khanna C, Hunter K. Modeling metastasis in vivo. Carcinogenesis 2005, 26:513-523.
17. Gravekamp C, Sypniewska R, Gauntt S, Tarango M, Rice P, Reddick R: Behavior of metastatic and nonmetastatic breast tumors in old mice. Exp Biol Med (Maywood) 2004, 229:665-675
18. Ottewell PD, Coleman RE, Holen I: From genetic abnormality to metastases: Murine models of breast cancer and their use in the development of anticancer therapies. Breast Cancer Res Treat 2005:1-13.
19. Aslakson CJ, Miller FR: Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992, 52:1399-1405.
20. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
21. Torrero MN, Henk WG, Li S: Regression of high-grade malignancy in mice by bleomycin and Interleukin-12 electrochemogenetherapy. Clin Cancer Res 2006,12:257-263
22. Hurst J, Maniar N, Tombarkiewicz J, Lucas F, Roberson C, Steplewski Z, James W, Perras J: A novel model of a metastatic human breast tumour xenograft line. Br J Cancer 1993, 68: 274-276.
23. Kim JB, O'Hare MJ, Stein R: Models of breast cancer: Is merging human and animal models the future? Breast Cancer Res 2004, 6:22-30.
24. Yoneda T, Michigan, T, Yi B, Williams PJ, Niewolna M, Hiraga T: Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 2000, 88:2979-2988.
25. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Condon-Cardo C, Guise TA, Maseagué J: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003. 3: 537-549.
26. Adwan H, Bauerie TJ, Berger MR: Downregulation of osteopontin and bone slaloprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther 2004, 11:109-120
27. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Oishen AB, Gerald WL, Messagué J: Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524.
28. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
29. Cabioglu N, Summy J, Miller C, Parikh NU, Sahin AA, Tuzlali S, Pumiglia K, Gallick GE, Price JE: CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res 2005, 65:6493-6497.
30. Kuperwasser C, Dessain S, Bierbaum BE, Garnet D, Sperandio K, Gauvin GP, Naber SP, Weinberg RA, Rosenblatt M: A mouse model of human breast cancer matastasis to human bone. Cancer Res 2005, 65:6130-6138.
31. Stewart TA, Pattengale PK, Leder P: Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 1984, 38:627-637.
32. Schoenenberger CA, Andres AC, Groner B, van der Valk M, LeMeur M, Gerlinger P: Targeted c-myc gene expression in mammary glands of transgenic mice induces mammary tumours with constitutive milk protein gene transcription. EMBO J 1988, 7:169-175.
33. Sandgren EP, Schroeder JA, Qui TH, Palmiter RD, Brinster RL, Lee DC: Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice. Cancer Res 1995, 55:3915-3927.
34. Cardiff RD, Anver MR, Gusterson BA, Hannighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, et al.: The mammary pathology of genetically engineered mice: The consensus report and recommendations from the Annapolis meeting. Oncogene 2000, 19:968-988.
35. Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P: Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 1987, 49:465-475.
36. Green JE, Shibata MA, Yoshidome K, Liu ML, Jorcyk C, Anver MR, Wigginton J, Wiltrout R, Shibata E, Kaczmarczyk S, et al.: The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: Ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 2000,18:1020-1027.
37. Gossen M, Bujard H: Tight control of gene expression in memmellan cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992,89:5547-5551.
38. Gunther EI, Belka GK, Wertheim GB, Wang J, Hartman JL, Boxer RB, Chodosh LA: A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J 2002, 16:283-292.
39. Sauer B, Henderson N: Cre-stimulated recombination, at loxP-containing DNA sequences placed into the mammalian genome. Nucleic Acids Res 1999, 17:147-161.
40. Wagner KU, Wall RJ, St-Onge L, Gruss P, Wynshaw-Boris A, Garrett L, Li M, Furth PA, Hennighausen L: Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res 1997, 25: 4323-4330.
41. Desai KV, Xiao N, Wang W, Gangi L, Greene J, Powell JI, Dickson R, Furth P, Hunter K, Kucherlapati R, et al: Initiating oncogenic event determines gene-expression patterns of human breast cancer model. Proc Natl Acad Sci USA 2002, 99:6967-6972.
42. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P: Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncongene. Cell 1988, 54: 105-116.
43. Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ, Notorfrancesco KL, Cardiff RD, Chodosh LA: The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 2006, 8:197-209.
44. Dankorl D, Maslikowski B, Warner N, Kanno N, Kim H, Wang Z, Moran MF, Oshima RG, Cardiff RD, Muller WJ: Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer. Mol Cell Biol 2001, 21: 1540-1551.
45. Guy CT, Cardiff RD, Muller WJ: Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol Cell Biol 1992, 12:954-961.
46. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW: Progression to malignancy in the polyome middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003, 163:2113-2126.
47. Maglione JE, Moghanaki D, Young LJ, Manner CK, Ellies LG, Joseph SO, Nicholson B, Cardiff RD, MacLeod CL: Transgenic Polyome middle-T mice model premalignant mammary disease, Cancer Res 2001, 61:8298-8305.
48. Lin EY, Nguyen AV, Russell RG, Pollard JW: Colony-stimulating factor 1 promotes progression a mammary tumors to malignancy. J Exp Med 2001, 193:727-740.
49. Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, Graf T, Pollard JW, Segall J, Condeelis J: A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 2004, 64:7022-7029.
50. Gouon-Evans V, Rothenberg ME, Pollard JW: Postnatal mammary gland development requires macrophages and eosinophils. Development 2000, 127:2269-2282.
51. Almholt K, Lund LR, Rygaard J, Nielsen BS, Dano K, Romer J, Johnsen M: Reduced metastasis of transgenic: Mammary cancer in urokinase-deficient mice. Int J Cancer 2005, 113; 525-532.
52. Bugge TH, Lund LR, Kombrinck KK, Nielsen BS, Holmback K, Drew AF, Flick MJ, Witte DP, Dano, K, Degen JL: Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 1998, 16:3097-3104.
53. Cuevas BD, Winter-Vann AM, Johnson NL, Johnson GL: MEKK1 controls matrix degredation and tumor cell dissemination during metastasis of polyome middle-T driven mammary cancer. Oncogene 2006.
54. Schroeder JA, Adriance MC, Thompson MC, Camenisch TD, Gendler SJ: MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene 2003, 22: 1324-1332.
55. Hoffman RM: Green fluorescent protein imaging of tumor cells in mice, Lab Anim (NY) 2002, 31:34-41.
56. Ahmed F, Wyckoff J, Lin EY, Wang W, Wang Y, Hennighausen L, Miyazaki J, Jones J, Pollard JW, Condeelis JS, et al.; GFP expression in the mammary gland for imaging of mammary tumor cells in transgenic mice. Cancer Res 2002, 62:7166-7169.
57. Lyons SK, Meuwissen R, Krimpenfort P, Berns A: The generation of a conditional reporter that anables bioluminescence imaging of Cre/ loxP-dependent turmorigenesis in mice. Cancer Res 2003, 63:7042-7046.
58. Kawamoto S, Niwa H, Tashiro, F, Sano, S, Kondoh G, Takeda J, Tabayeshi K, Miyazaki J: A novel reporter mouse, strains that expresses enhanced green fluorescent protein upon Cremediated, recombination. FEBS Lett 2000, 470:263-268.
59. Dubey P, So H, Adonai N, Du S, Rosalo, A, Braun J, Gambhir SS, Witle ON: Quantitative imaging of the T cell antitumor response by positron-emission tomography. Proc, Natl Acad Sci, USA 2003, 100:1232-1237.
60. Naurnov GN, Wilson SM, MacDonald IC, Schmidt EE, Morris VL, Groom AC, Hoffman RM, Chambers AF: Cellular expression of green fluorescent protein, coupled with high-resolution in vivo videomicroscopy, to monitor steps in tumor metastasis. J Cell Sci 1999, 112:1835-1842.
61. Sweeney TJ, Mailander V, Tucker AA, Olomu AB, Zhang W, Cao Y, Negrin RS, Contag CH: Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci USA 1999, 96: 12044-12049.
62. Condeelis J, Segall JE: Intravital imaging of cell movement in tumours. Natl Rev Cancer 2003, 3:221-930.
63. Chambers AF, MacDonald IC, Schmidt EE, Koop S, Morris VL, Khokha R, Groom AC: Steps in tuNor matastasis: new concepts from intravital videomicroscopy. Cancer Metastasis Rev 1995, 14:279-301.
64. Georgakoudi I, Solban N, Noval J, Rice WL, Wai X, Hasan T, Lin CP: In vivo flow cytometry. a new method for enumerating circulating cancer cells. Cancer Res 2004, 64:5044-5047.
65. Yin JJ, Selander K, Chirgwin JM, Dallas M. Grubbs BG, Wieser R, Massagué J, Mundy GR, Guise TA: TGF-beta signaling blockede inhibits PTHrP secretion by breast cancer cells and bone metastasis development. J Clin Invest 1999, 103:197-206.
66. Muraoka RS, Koh Y, Roebuck LR, Sanders ME, Brantley-Sieders D, Gorska AE, Moses HL, Arteaga CL: Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol Cell Biol 2003, 23:8691-8703.
67. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massagué J: Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 2003, 100:8430-8435.
68. Muraoka-Cook RS, Kurokawa H, Koh Y, Forbes JT, Roebuck LR, Barcelioa-Hoff MH, Moody SE, Chodosh LA, Arteaga CL: Conditional of overexpression of active transforming growth factor beta1 in vivo accelerates metastasis of transgenic, mammary tumors. Cancer Res 2004, 64:9002-9011.
69. Forrester E, Chytil A, Bierie, B, Aakre, M, Gorska AE, Sharif-Afshar AR, Muller WJ, Mosses, HL: Effect a conditional knockout of the type II TGF-beta receptor gene in mammary epithelle on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res 2005, 65:2296-2302.
70. Yang YA, Dukhanina O, Tang B, Mamura M, Letterio JJ, MacGragor J, Patel SC, Khozin S, Liu ZY, Green J, et al.: Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side affects. J Clin Invest 2002, 109:1607-1615.
71. Dumont N, Arteaga CL: Targeting the TGF beta signaling network, in human neoplasia. Cancer Cell 2003, 3:531-536.
72. Pierce DF Jr, Gorska AE, Chytil A, Meisa KS, Page DL, Cofley RJ Jr, Moses HL: Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc Natl Acad Sci USA 1995, 92:4254-4258.
73. Ross JS, Relcher JA: The HER-2/neu Pncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells, 1998, 16:413-428.
74. Zhang G, He B, Weber GF: Growth factor signaling induces, metastasis genes in transformed cells: Molecular connection between Akt kinase and osteopontin in breast cancer. Mol Cell Biol 2003, 23:6507-6519.
75. Xue C, Liang F, Mahmood R, Vuolo M, Wyckoff J, Oian H, Tsai KL, Kim M, Locker J, Zhang ZY, Segall JE: ErbB3-dependent motility and intravasation in breast cancer metastasis. Cancer Res 2006, 66:1418-1426.
76. Xue C, Wyckoff J, Liang F, Sidani M, Violini S, Tsai KL, Zhang ZY, Sahai E, Condeelis J, Segall JE: Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravation and metastasis. Cancer Res 2006. 66:192-197.
77. Kwan H, Pecenka V, Tsukamoto, A, Paralow TG, Guzman R, Lin TP, Muller WJ, Lee FS, Leder P, Varmus HE: Transgenes, expressing the Wnt-1 and Int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice. Mol Cell Biol 1992, 12:147-154.
78. Kolonin M, Pasqualini R, Arap W: Molecular addresses in blood vessels as targets for therapy. Curr Opin Chem Biol 2001, 5: 308-313.
79. Fidler IJ: The organ microenvironment and cancer metastasis Differentiation 2002, 70:498-505.
80. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
81. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H: Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 2005, 65:967-971.
82. Liang Z, Wu T, Lou H, Yu X, Taichman RS, Lau SK, Nie S, Umbreit J, Shim H: Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 2004, 64:4302-4308.
83. Tuck AB, Arsenault DM, O'Malley FP, Hota C, Ling MC, Wilson SM, Chambers AF: Osteopontin induces increased invasiveness. and plasminogen activator expression of human mammary epithelial cells. Oncogene 1999, 18:4237-4246
84. Kharl SA, Cook AC, Kappil M, Gunihert U, Chambers AF, Tuck AB, Denhardt DT: Enhanced cell surface CD44 varlant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: Novel post-transcriptional, post-translational regulation. Clin Exp Metastasis 2006.
85. Lee H, Lin EC, Liu L, Smith JW: Gene impression profiling of tumor xenografts: In vivo analysis of organ-specific metastasis. Int J Cancer 2003, 107:528-534.
86. Ventyghem SA, Allan AL, Postenka CO, Al-Katib W, Keeney M, Tuck AB, Chambers AF: A new model for lymDhatic metastasis: development of a variant of the MDA-MB-468 human breast cancer cell line that aggressively metastasis to lymph nodes. Clin Exp Metastasis 2005, 22:351-381.
87. Seito H, Tsunenari T, Onuma E, Sato K, Ogata E, Yamada-Okabe H: Humanized monoclonal antibody against parathyroid hormone-ralated protein suppresses osteolytic bone metastasis of human breast cancer cells derived from MDA-MB-231. Anticancer Res 2005, 25:3817-3823.
88. Jones DH, Nakashima T, Sanches OH, Kazieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, et al.: Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006, 440:692-696.
89. Morony S, Capperelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ: Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngenic and nude mouses models of experimental bone metastasis. Cancer Res 2001, 61:4432-4436.
90. Fisher JL, Thomas-Mudge RJ, Elliott J, Hards DK, Sims NA, Slavin J, Martin TJ, Gillespie MT: Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res 2006, 66:3620-3628.
91. Schoeffner DJ, Matheny SL, Akahane T, Fartor V, Barry A, Merlino G, Thorgeirsson UP: VEGF contributes to mammary tumor growth in transgenic mice through paracrin and autocrine mechanisms. Lab Invest 2005, 85:608-623.
92. Kim LS, Huang S, Lu W, Lev DC, Price JE: Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastasis in nude mice. Clin Exp Metastasis 2004, 21:107-118
93. Skoba M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M: Induction of tumor lymphanglogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001, 7:192-198.
94. Mattila MM, Ruohola JK, Karpanen T, Jackson DG, Alitalo K, Harkonen PL: VEGF-C induced lymphanglogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors Int J Cancer 2002, 98:946-951.
95. Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, Pytowski B, Skoba M: Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastasis than inactivation of VEGFR-2 Cancer Res 2006, 66:2650-2657.
96. Hennighausen L: The mammary gPand as a bioreactor: production of foreign proteins in milk. Protein Expr Purif 1990, 1:3-8.
97. Lipnik K, Petznek H, Renner-Muller I, Egerbacher M, Url A, Salmons B, Gunzburg WH, Hohenadl C: A 470 bp WAP-promoter fragment confers lactation independent, progesterone regulated mammary-specific gene expression in transgenic mice. Transgenic Res 2005, 14:145-158.
98. Ali S, Clark AJ: Charcterization of the gene encoding ovine beta-lactoglubulin. Similarity to the genes for retinol binding protein and other secretory proteins. J Mol Biol 1988, 199: 415-426.
99. Bortner DM, Rosenberg MP: Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol 1997, 17:453-459.
100. Palmiter RD, Sandgren EP, Koeller DM, Brinster RL: Distal regulatory elements from the mouse metallothionein locus stimulate gene expression in transgenic mice. Mol Cell Biol 1993, 13:5266-5275.
101. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hia T: Overexpression of cyclooxygenase-2 is sufficient to induce turmorigenesis in transgenic mice. J Biol Chem 2001, 276:18563-18569.
102. Guy GT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ: Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992. 89:10578-10582.
103. Moody SE, Sarkisian CJ, Hahn KT, Gunther EJ, Pickup S, Dugan KD, Innocent N, Cardiff RD, Schnall MD, Chodosh LA: Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2002, 2:451-461.
104. Jeffers M, Fiecella M, Webb CP, Anver M, Koochekpour S, Vande Woude GF: The mutationally activated met receptor mediates motility and metastasis. Proc Natl Acad Sci USA 1998, 95:14417-14422.
105. Maroulakou IG, Anver M, Garreti L, Green JE: Prostate and mammary edenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA 1994, 91:11236-11240.
106. Gallahan D, Jhappan C, Robinson G, Hennighausen L, Sharp R, Kordon E, Callahan R, Merlino G, Smith GH: Expression of a truncated Int3 gene in developing secretory mammary ephithelium specifically retards lobular differentiation resulting in tumorigenesis. Cancer Res 1996, 56:1775-1785.
107. Schulze-Garg C, Lohler J, Gocht A. Deppert W: A Transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland. Oncogene 2000, 19:1028-1037.
108. Nielsen LL, Discalani CM, Gurnani M, Tyter RD: Histopathology of salivary and mammary gland tumors in transgenic mice expressing a human Ha-ras oncogene. Cancer Res 1991, 51: 3762-3767.
109. Gallego MI, Bierie B, Hennighausen L: Targeted expression of HGF/SF in mouse mammary epithelium leads to metastasic adenosquamous carcinomas through the activation of multiple signal transduction pathways. Oncogene 2003, 22:8498-8508.
110. Pravtcheva DD, Wise TL: Metastasizing mammary carcinomas in H19 enhancers-Igf2 transgenic mice. J Exp Zool 1998, 281: 43-57,
111. Lin SC, Lee KF, Nikitin AY, Hilsenbeck SG, Cardiff RD, Li A, Kang KW, Frank SA, Leo WH, Lee EY: Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res 2004, 64:3525-3532.
112. Ridgeway AG, McMenamin J, Leder P: P53 levels determine outcome during beta-catenin tumor initiation and metastasis in the mammary gland and make germ cells. Oncogene 2006.
113. Davies MP, Rudland PS, Robertson L, Parry EW, Jolicoeur P, Barraclough R: Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic mice induces metastasis of mammary tumours. Oncogene 1996, 13:1631-1637.